BIO-GENE TECHNOLOGY LTD - Announcements

0.00%

1.9¢

Market Cap $5.796M

Chemicals Chemicals

Bio-Gene Technology Limited is an Australia-based agriculture technology development... Bio-Gene Technology Limited is an Australia-based agriculture technology development company enabling the next generation of novel insecticides derived from nature to achieve high impact globally. Its technology is based on compounds with a novel mode of action proven to overcome insecticide resistance with minimal impact on human health and the environment. The Company’s technology provides multiple potential new solutions in applications across crop protection, grain storage, public health, and consumer products. It is developing and commercialising a broad portfolio of targeted insect control and pest management solutions. The Company's lead beta-triketone insecticide products include Flavocide and Qcide. Flavocide is a chemically synthesized product based on flavesone. Qcide is a natural oil product containing tasmanone as the active constituent. The Company operates in one business segment, being the conduct of research and development activities in the agricultural sector.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

Filters [Clear]

Price Sensitive: Yes

BGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/07/25	693.99KB	Share
BGT	Result of Security Purchase Plan	PRICE SENSITIVE	02/06/25	141.73KB	Share
BGT	Launch of Security Purchase Plan	PRICE SENSITIVE	12/05/25	855.68KB	Share
BGT	Investor Presentation - Placement	PRICE SENSITIVE	05/05/25	2.26MB	Share
BGT	Result of Placement	PRICE SENSITIVE	05/05/25	216.78KB	Share
BGT	Trading Halt	PRICE SENSITIVE	01/05/25	212.03KB	Share
BGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/04/25	441.4KB	Share
BGT	Bio-Gene Presentation - NWR Virtual Healthcare Conference	PRICE SENSITIVE	20/03/25	2.17MB	Share
BGT	Appendix 4D and Half-Year Accounts 31 December 2024	PRICE SENSITIVE	27/02/25	856.88KB	Share
BGT	BGT Investor Webinar 4-Feb-25 Slides	PRICE SENSITIVE	04/02/25	571.46KB	Share
BGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/01/25	440.94KB	Share
BGT	BGT Awarded U.S. Department of Defense Grants	PRICE SENSITIVE	29/01/25	250.94KB	Share
BGT	CEO's Address to Shareholders	PRICE SENSITIVE	29/11/24	277.2KB	Share
BGT	CEO's Presentation	PRICE SENSITIVE	29/11/24	1MB	Share
BGT	Chair's Address to Shareholders	PRICE SENSITIVE	29/11/24	143.36KB	Share
BGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/24	436.59KB	Share
BGT	Bio-Gene Receives $535000 R&D Tax Incentive	PRICE SENSITIVE	25/10/24	201.27KB	Share
BGT	BGT Investor Presentation Oct24	PRICE SENSITIVE	02/10/24	1.59MB	Share
BGT	Investor Webinar Presentation 06 Sep 24	PRICE SENSITIVE	06/09/24	3.71MB	Share
BGT	Bio-Gene & Rallis achieve key Flavocide production milestone	PRICE SENSITIVE	02/09/24	280.58KB	Share
BGT	Appendix 4E and 2024 Annual Report	PRICE SENSITIVE	28/08/24	1.77MB	Share
BGT	Envu collaboration on Flavocide for mosquito management	PRICE SENSITIVE	14/08/24	191.05KB	Share
BGT	APVMA Pre Application Assistance	PRICE SENSITIVE	08/08/24	202.82KB	Share
BGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/07/24	448.66KB	Share
BGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/04/24	1.36MB	Share
BGT	Investor Webinar - FY24 Half Year Review	PRICE SENSITIVE	05/03/24	3.87MB	Share
BGT	Appendix 4D - Half Year Accounts - 31 December 2023	PRICE SENSITIVE	26/02/24	974.62KB	Share
BGT	Appendix 4C - 31 December 2023	PRICE SENSITIVE	29/01/24	816.66KB	Share
BGT	Bio-Gene Receives R&D Tax Incentive	PRICE SENSITIVE	19/01/24	613.55KB	Share
BGT	Investor Webinar - Prof. Catherine Hill and CEO Tim Grogan	PRICE SENSITIVE	13/12/23	17.99MB	Share
BGT	BGT Corporate Presentation	PRICE SENSITIVE	13/12/23	3.71MB	Share
BGT	BGT 2023AGM - CEO's Presentation	PRICE SENSITIVE	23/11/23	1.85MB	Share
BGT	BGT 2023AGM - CEO's Address	PRICE SENSITIVE	23/11/23	243.14KB	Share
BGT	BGT 2023AGM - Chairman's Address	PRICE SENSITIVE	23/11/23	627.29KB	Share
BGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	30/10/23	797.36KB	Share
BGT	Result of Share Purchase Plan Offer (SPP)	PRICE SENSITIVE	03/10/23	638.43KB	Share
BGT	Launch of SPP & Further Funds Raised under Placement	PRICE SENSITIVE	12/09/23	897.77KB	Share
BGT	Result of Placement	PRICE SENSITIVE	05/09/23	629.09KB	Share
BGT	Capital Raise & Presentation	PRICE SENSITIVE	01/09/23	1.89MB	Share
BGT	Trading Halt	PRICE SENSITIVE	01/09/23	761.08KB	Share
BGT	BGT Update Company Presentation	PRICE SENSITIVE	11/08/23	1.42MB	Share
BGT	New USA Patent for the Insecticide Market	PRICE SENSITIVE	02/08/23	774.9KB	Share
BGT	Appendix 4E and 2023 Annual Report	PRICE SENSITIVE	31/07/23	2.36MB	Share
BGT	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	28/07/23	1.71MB	Share
BGT	BGT Appoints New CEO	PRICE SENSITIVE	28/07/23	890.22KB	Share
BGT	BGT Executes Agreement with STK	PRICE SENSITIVE	27/07/23	829.49KB	Share
BGT	BGT selected for USA CDC Funded Program	PRICE SENSITIVE	24/07/23	816.89KB	Share
BGT	Allowance of USA Patent	PRICE SENSITIVE	28/06/23	735.02KB	Share
BGT	GRDC Confirms Support for Flavocide in Grain Storage	PRICE SENSITIVE	11/05/23	788.86KB	Share
BGT	Bio-Gene Update Company Presentation	PRICE SENSITIVE	03/05/23	829.75KB	Share
BGT	Appendix 4C - 31 March 2023	PRICE SENSITIVE	27/04/23	864.2KB	Share
BGT	Synergy Studies Offer Significant Commercial Opportunities	PRICE SENSITIVE	26/04/23	688.39KB	Share
BGT	Board and Management Changes	PRICE SENSITIVE	24/04/23	257.26KB	Share
BGT	Bio-Gene Extends Commercial Development Agreement	PRICE SENSITIVE	13/04/23	287.54KB	Share
BGT	Allowance of United States Patent	PRICE SENSITIVE	17/03/23	241.64KB	Share
BGT	Bio-Gene Company Update Presentation	PRICE SENSITIVE	23/02/23	1.2MB	Share
BGT	Appendix 4D - Half Year Accounts - 31 December 2022	PRICE SENSITIVE	23/02/23	754.92KB	Share
BGT	Appendix 4C - 31 December 2022	PRICE SENSITIVE	31/01/23	465.87KB	Share
BGT	Bio-Gene Receives R&D Tax Incentive	PRICE SENSITIVE	20/01/23	223.63KB	Share
BGT	Bio-Gene and STK Agree Binding Terms on Global Collaboration	PRICE SENSITIVE	19/01/23	280.95KB	Share
BGT	Trading Halt	PRICE SENSITIVE	18/01/23	124.03KB	Share
BGT	Bio-Gene Submits Application for Plant Breeders Rights	PRICE SENSITIVE	01/12/22	271.23KB	Share
BGT	Appendix 4C - 30 September 2022	PRICE SENSITIVE	27/10/22	815.71KB	Share
BGT	Significant Developments in Molecule Manufacturing - Update	PRICE SENSITIVE	26/10/22	648.19KB	Share
BGT	Appendix 4E and 2022 Annual Report	PRICE SENSITIVE	16/08/22	1.64MB	Share
BGT	Appendix 4C - 30 June 2022	PRICE SENSITIVE	28/07/22	460.53KB	Share
BGT	Update on Development Program with BASF	PRICE SENSITIVE	11/05/22	236.01KB	Share
BGT	Appendix 4C - 31 March 2022	PRICE SENSITIVE	27/04/22	462.92KB	Share
BGT	Bio-Gene Executes Commercial Development Agreement	PRICE SENSITIVE	04/04/22	264.65KB	Share
BGT	Strategic Placement of $1.5 million to Cornerstone Investor	PRICE SENSITIVE	15/03/22	246.06KB	Share
BGT	Positive Stored Grain Pest Results	PRICE SENSITIVE	07/03/22	253.46KB	Share
BGT	Grant of United States Patent	PRICE SENSITIVE	02/03/22	237.2KB	Share
BGT	Appendix 4D - Half Year Accounts - 31 December 2021	PRICE SENSITIVE	17/02/22	858.68KB	Share
BGT	Bio-Gene Receives R&D Tax Incentive	PRICE SENSITIVE	09/02/22	221.05KB	Share
BGT	Appendix 4C - 31 December 2021	PRICE SENSITIVE	31/01/22	479.48KB	Share
BGT	Bio-Gene Completes Capital Raising of $3.2 Million	PRICE SENSITIVE	09/12/21	247.5KB	Share
BGT	Trading Halt	PRICE SENSITIVE	07/12/21	536.77KB	Share
BGT	Bio-Gene to Progress Synergy Research	PRICE SENSITIVE	06/12/21	233.83KB	Share
BGT	Bio-Gene 2021 AGM - CEO's Presentation	PRICE SENSITIVE	30/11/21	239.69KB	Share
BGT	Bio-Gene 2021 AGM - Chairman's Address	PRICE SENSITIVE	30/11/21	281.72KB	Share
BGT	Bio-Gene 2021 AGM Presentation	PRICE SENSITIVE	30/11/21	821.71KB	Share
BGT	Appendix 4C - 30 September 2021	PRICE SENSITIVE	28/10/21	492.63KB	Share
BGT	Bio-Gene Executes Option Agreement with Clarke	PRICE SENSITIVE	27/10/21	278.61KB	Share
BGT	Bio-Gene Commercial Agreement with Evergreen Garden Care	PRICE SENSITIVE	25/10/21	266.56KB	Share
BGT	Successful Allowance of New United States Patent	PRICE SENSITIVE	14/10/21	236.31KB	Share
BGT	Appendix 4E and 2021 Annual Report	PRICE SENSITIVE	26/08/21	1.65MB	Share
BGT	Appendix 4C - 30 June 2021	PRICE SENSITIVE	21/07/21	469.93KB	Share
BGT	Successful Allowance of Additional New Australian Patent	PRICE SENSITIVE	09/06/21	235.91KB	Share
BGT	Successful Allowance of New Australian Patent	PRICE SENSITIVE	08/06/21	235.35KB	Share
BGT	Stored Grain Trial Results Confirm Control of Key Pests	PRICE SENSITIVE	12/05/21	263.02KB	Share
BGT	Appendix 4C - 31 March 2021	PRICE SENSITIVE	30/04/21	564.61KB	Share
BGT	Flavocide MOA Studies Confirm Target Site of Activity	PRICE SENSITIVE	24/02/21	239.17KB	Share
BGT	Appendix 4D - Half Yearly Report and Accounts - 31/12/20	PRICE SENSITIVE	18/02/21	812.66KB	Share
BGT	Appendix 4C - 31 December 2020	PRICE SENSITIVE	29/01/21	482.8KB	Share
BGT	Further Positive Results Reinforce Environmental Safety	PRICE SENSITIVE	21/01/21	244.35KB	Share
BGT	Positive Eco-Tox Safety Results for Flavocide	PRICE SENSITIVE	08/12/20	318.03KB	Share
BGT	Results of Meeting	PRICE SENSITIVE	26/11/20	278.74KB	Share
BGT	Bio-Gene 2020 AGM - CEO's Address	PRICE SENSITIVE	26/11/20	246.9KB	Share
BGT	Bio-Gene 2020 AGM - Meeting Chairman's Address	PRICE SENSITIVE	26/11/20	270.73KB	Share
BGT	Bio-Gene 2020 AGM Presentation	PRICE SENSITIVE	26/11/20	2.62MB	Share

BGT Quarterly Activities/Appendix 4C Cash Flow Report
31/07/25	PRICE SENSITIVE	693.99KB	Share
BGT Result of Security Purchase Plan
02/06/25	PRICE SENSITIVE	141.73KB	Share
BGT Launch of Security Purchase Plan
12/05/25	PRICE SENSITIVE	855.68KB	Share
BGT Investor Presentation - Placement
05/05/25	PRICE SENSITIVE	2.26MB	Share
BGT Result of Placement
05/05/25	PRICE SENSITIVE	216.78KB	Share
BGT Trading Halt
01/05/25	PRICE SENSITIVE	212.03KB	Share
BGT Quarterly Activities/Appendix 4C Cash Flow Report
30/04/25	PRICE SENSITIVE	441.4KB	Share
BGT Bio-Gene Presentation - NWR Virtual Healthcare Conference
20/03/25	PRICE SENSITIVE	2.17MB	Share
BGT Appendix 4D and Half-Year Accounts 31 December 2024
27/02/25	PRICE SENSITIVE	856.88KB	Share
BGT BGT Investor Webinar 4-Feb-25 Slides
04/02/25	PRICE SENSITIVE	571.46KB	Share
BGT Quarterly Activities/Appendix 4C Cash Flow Report
30/01/25	PRICE SENSITIVE	440.94KB	Share
BGT BGT Awarded U.S. Department of Defense Grants
29/01/25	PRICE SENSITIVE	250.94KB	Share
BGT CEO's Address to Shareholders
29/11/24	PRICE SENSITIVE	277.2KB	Share
BGT CEO's Presentation
29/11/24	PRICE SENSITIVE	1MB	Share
BGT Chair's Address to Shareholders
29/11/24	PRICE SENSITIVE	143.36KB	Share
BGT Quarterly Activities/Appendix 4C Cash Flow Report
31/10/24	PRICE SENSITIVE	436.59KB	Share
BGT Bio-Gene Receives $535000 R&D Tax Incentive
25/10/24	PRICE SENSITIVE	201.27KB	Share
BGT BGT Investor Presentation Oct24
02/10/24	PRICE SENSITIVE	1.59MB	Share
BGT Investor Webinar Presentation 06 Sep 24
06/09/24	PRICE SENSITIVE	3.71MB	Share
BGT Bio-Gene & Rallis achieve key Flavocide production milestone
02/09/24	PRICE SENSITIVE	280.58KB	Share
BGT Appendix 4E and 2024 Annual Report
28/08/24	PRICE SENSITIVE	1.77MB	Share
BGT Envu collaboration on Flavocide for mosquito management
14/08/24	PRICE SENSITIVE	191.05KB	Share
BGT APVMA Pre Application Assistance
08/08/24	PRICE SENSITIVE	202.82KB	Share
BGT Quarterly Activities/Appendix 4C Cash Flow Report
30/07/24	PRICE SENSITIVE	448.66KB	Share
BGT Quarterly Activities/Appendix 4C Cash Flow Report
29/04/24	PRICE SENSITIVE	1.36MB	Share
BGT Investor Webinar - FY24 Half Year Review
05/03/24	PRICE SENSITIVE	3.87MB	Share
BGT Appendix 4D - Half Year Accounts - 31 December 2023
26/02/24	PRICE SENSITIVE	974.62KB	Share
BGT Appendix 4C - 31 December 2023
29/01/24	PRICE SENSITIVE	816.66KB	Share
BGT Bio-Gene Receives R&D Tax Incentive
19/01/24	PRICE SENSITIVE	613.55KB	Share
BGT Investor Webinar - Prof. Catherine Hill and CEO Tim Grogan
13/12/23	PRICE SENSITIVE	17.99MB	Share
BGT BGT Corporate Presentation
13/12/23	PRICE SENSITIVE	3.71MB	Share
BGT BGT 2023AGM - CEO's Presentation
23/11/23	PRICE SENSITIVE	1.85MB	Share
BGT BGT 2023AGM - CEO's Address
23/11/23	PRICE SENSITIVE	243.14KB	Share
BGT BGT 2023AGM - Chairman's Address
23/11/23	PRICE SENSITIVE	627.29KB	Share
BGT Quarterly Activities/Appendix 4C Cash Flow Report
30/10/23	PRICE SENSITIVE	797.36KB	Share
BGT Result of Share Purchase Plan Offer (SPP)
03/10/23	PRICE SENSITIVE	638.43KB	Share
BGT Launch of SPP & Further Funds Raised under Placement
12/09/23	PRICE SENSITIVE	897.77KB	Share
BGT Result of Placement
05/09/23	PRICE SENSITIVE	629.09KB	Share
BGT Capital Raise & Presentation
01/09/23	PRICE SENSITIVE	1.89MB	Share
BGT Trading Halt
01/09/23	PRICE SENSITIVE	761.08KB	Share
BGT BGT Update Company Presentation
11/08/23	PRICE SENSITIVE	1.42MB	Share
BGT New USA Patent for the Insecticide Market
02/08/23	PRICE SENSITIVE	774.9KB	Share
BGT Appendix 4E and 2023 Annual Report
31/07/23	PRICE SENSITIVE	2.36MB	Share
BGT Quarterly Activities/Appendix 4C Cash Flow Report
28/07/23	PRICE SENSITIVE	1.71MB	Share
BGT BGT Appoints New CEO
28/07/23	PRICE SENSITIVE	890.22KB	Share
BGT BGT Executes Agreement with STK
27/07/23	PRICE SENSITIVE	829.49KB	Share
BGT BGT selected for USA CDC Funded Program
24/07/23	PRICE SENSITIVE	816.89KB	Share
BGT Allowance of USA Patent
28/06/23	PRICE SENSITIVE	735.02KB	Share
BGT GRDC Confirms Support for Flavocide in Grain Storage
11/05/23	PRICE SENSITIVE	788.86KB	Share
BGT Bio-Gene Update Company Presentation
03/05/23	PRICE SENSITIVE	829.75KB	Share
BGT Appendix 4C - 31 March 2023
27/04/23	PRICE SENSITIVE	864.2KB	Share
BGT Synergy Studies Offer Significant Commercial Opportunities
26/04/23	PRICE SENSITIVE	688.39KB	Share
BGT Board and Management Changes
24/04/23	PRICE SENSITIVE	257.26KB	Share
BGT Bio-Gene Extends Commercial Development Agreement
13/04/23	PRICE SENSITIVE	287.54KB	Share
BGT Allowance of United States Patent
17/03/23	PRICE SENSITIVE	241.64KB	Share
BGT Bio-Gene Company Update Presentation
23/02/23	PRICE SENSITIVE	1.2MB	Share
BGT Appendix 4D - Half Year Accounts - 31 December 2022
23/02/23	PRICE SENSITIVE	754.92KB	Share
BGT Appendix 4C - 31 December 2022
31/01/23	PRICE SENSITIVE	465.87KB	Share
BGT Bio-Gene Receives R&D Tax Incentive
20/01/23	PRICE SENSITIVE	223.63KB	Share
BGT Bio-Gene and STK Agree Binding Terms on Global Collaboration
19/01/23	PRICE SENSITIVE	280.95KB	Share
BGT Trading Halt
18/01/23	PRICE SENSITIVE	124.03KB	Share
BGT Bio-Gene Submits Application for Plant Breeders Rights
01/12/22	PRICE SENSITIVE	271.23KB	Share
BGT Appendix 4C - 30 September 2022
27/10/22	PRICE SENSITIVE	815.71KB	Share
BGT Significant Developments in Molecule Manufacturing - Update
26/10/22	PRICE SENSITIVE	648.19KB	Share
BGT Appendix 4E and 2022 Annual Report
16/08/22	PRICE SENSITIVE	1.64MB	Share
BGT Appendix 4C - 30 June 2022
28/07/22	PRICE SENSITIVE	460.53KB	Share
BGT Update on Development Program with BASF
11/05/22	PRICE SENSITIVE	236.01KB	Share
BGT Appendix 4C - 31 March 2022
27/04/22	PRICE SENSITIVE	462.92KB	Share
BGT Bio-Gene Executes Commercial Development Agreement
04/04/22	PRICE SENSITIVE	264.65KB	Share
BGT Strategic Placement of $1.5 million to Cornerstone Investor
15/03/22	PRICE SENSITIVE	246.06KB	Share
BGT Positive Stored Grain Pest Results
07/03/22	PRICE SENSITIVE	253.46KB	Share
BGT Grant of United States Patent
02/03/22	PRICE SENSITIVE	237.2KB	Share
BGT Appendix 4D - Half Year Accounts - 31 December 2021
17/02/22	PRICE SENSITIVE	858.68KB	Share
BGT Bio-Gene Receives R&D Tax Incentive
09/02/22	PRICE SENSITIVE	221.05KB	Share
BGT Appendix 4C - 31 December 2021
31/01/22	PRICE SENSITIVE	479.48KB	Share
BGT Bio-Gene Completes Capital Raising of $3.2 Million
09/12/21	PRICE SENSITIVE	247.5KB	Share
BGT Trading Halt
07/12/21	PRICE SENSITIVE	536.77KB	Share
BGT Bio-Gene to Progress Synergy Research
06/12/21	PRICE SENSITIVE	233.83KB	Share
BGT Bio-Gene 2021 AGM - CEO's Presentation
30/11/21	PRICE SENSITIVE	239.69KB	Share
BGT Bio-Gene 2021 AGM - Chairman's Address
30/11/21	PRICE SENSITIVE	281.72KB	Share
BGT Bio-Gene 2021 AGM Presentation
30/11/21	PRICE SENSITIVE	821.71KB	Share
BGT Appendix 4C - 30 September 2021
28/10/21	PRICE SENSITIVE	492.63KB	Share
BGT Bio-Gene Executes Option Agreement with Clarke
27/10/21	PRICE SENSITIVE	278.61KB	Share
BGT Bio-Gene Commercial Agreement with Evergreen Garden Care
25/10/21	PRICE SENSITIVE	266.56KB	Share
BGT Successful Allowance of New United States Patent
14/10/21	PRICE SENSITIVE	236.31KB	Share
BGT Appendix 4E and 2021 Annual Report
26/08/21	PRICE SENSITIVE	1.65MB	Share
BGT Appendix 4C - 30 June 2021
21/07/21	PRICE SENSITIVE	469.93KB	Share
BGT Successful Allowance of Additional New Australian Patent
09/06/21	PRICE SENSITIVE	235.91KB	Share
BGT Successful Allowance of New Australian Patent
08/06/21	PRICE SENSITIVE	235.35KB	Share
BGT Stored Grain Trial Results Confirm Control of Key Pests
12/05/21	PRICE SENSITIVE	263.02KB	Share
BGT Appendix 4C - 31 March 2021
30/04/21	PRICE SENSITIVE	564.61KB	Share
BGT Flavocide MOA Studies Confirm Target Site of Activity
24/02/21	PRICE SENSITIVE	239.17KB	Share
BGT Appendix 4D - Half Yearly Report and Accounts - 31/12/20
18/02/21	PRICE SENSITIVE	812.66KB	Share
BGT Appendix 4C - 31 December 2020
29/01/21	PRICE SENSITIVE	482.8KB	Share
BGT Further Positive Results Reinforce Environmental Safety
21/01/21	PRICE SENSITIVE	244.35KB	Share
BGT Positive Eco-Tox Safety Results for Flavocide
08/12/20	PRICE SENSITIVE	318.03KB	Share
BGT Results of Meeting
26/11/20	PRICE SENSITIVE	278.74KB	Share
BGT Bio-Gene 2020 AGM - CEO's Address
26/11/20	PRICE SENSITIVE	246.9KB	Share
BGT Bio-Gene 2020 AGM - Meeting Chairman's Address
26/11/20	PRICE SENSITIVE	270.73KB	Share
BGT Bio-Gene 2020 AGM Presentation
26/11/20	PRICE SENSITIVE	2.62MB	Share

REFRESH

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

(20min delay)
Last 1.9¢		Change 0.000(0.00%)		Mkt cap ! $5.796M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
3	340055	1.9¢

Sellers (Offers)

Price($)	Vol.	No.
2.1¢	341825	2

View Market Depth

No.	Vol.	Price($)
3	340055	0.019
4	533056	0.018
5	1030631	0.017
6	1026233	0.016
5	855000	0.015

Price($)	Vol.	No.
0.021	341825	2
0.022	270000	1
0.023	753293	4
0.024	300000	1
0.025	150000	1

Last trade - 11.00am 01/08/2025 (20 minute delay)

BGT (ASX) Chart

Day chart unavailable

BIO-GENE TECHNOLOGY LTD - Announcements

Corporate Spotlight
Not Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Codeifai looks to ride AI wave as Quantum Computing becomes a necessity

Prospect Resources: Replicating the success of Arcadia with ~1b tonne copper ore target

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

Top Stories

BIO-GENE TECHNOLOGY LTD - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Codeifai looks to ride AI wave as Quantum Computing becomes a necessity

Prospect Resources: Replicating the success of Arcadia with ~1b tonne copper ore target

Infini Resources appoints Rohan Bone as CEO ahead of Phase 2 campaign

Resolution Minerals appoints industry experts to fast-track US growth strategy

Top Stories

Corporate Spotlight
Not Yet Available